8-K: Indivior Sets 2026 Financial Guidance, Accelerates SUBLOCADE Growth

Indivior PLC announced its full-year 2026 financial guidance, projecting accelerated SUBLOCADE revenue growth and significant adjusted EBITDA expansion driven by a simplified operating model.

Summary

• Full-year 2026 Total Net Revenue is expected in the range of $1,125 million to $1,195 million.
• Full-year 2026 Total SUBLOCADE Net Revenue is expected to be in the range of $905 million to $945 million, representing 11% growth at the midpoint.
• Full-year 2026 Non-GAAP Operating Expenses are expected in the range of $430 million to $450 million, reflecting at least $150 million in annual savings.
• Full-year 2026 Adjusted EBITDA is expected in the range of $535 million to $575 million, representing 35% growth at the midpoint and a 14 percentage point margin expansion.
• The company completed Phase I of its Indivior Action Agenda ('Generate Momentum') and entered Phase II ('Accelerate') on January 1, 2026.
• Indivior gained inclusion in the S&P SmallCap 600 index effective December 22, 2025.
• Shareholders approved the company's proposal to change its domicile from the U.K. to the U.S., expected to take effect on January 26, 2026.
• The legacy U.S. Department of Justice matter was concluded with a full payment of the outstanding obligation of $295 million.
• SUBLOCADE dispense unit growth is expected to accelerate from approximately 7% in 2025 to the mid-teens in 2026.
• Approximately $300 million in cash flow from operations is expected in 2026.

Sentiment

Score: 8

Explanation: The guidance indicates strong profitability and operational efficiency improvements, driven by cost savings and accelerated growth of the key product, SUBLOCADE. While total revenue is slightly down due to other product lines, the focus on the core growth driver and margin expansion is very positive.

Positives

• Projected 35% growth in Adjusted EBITDA and 14 percentage points of Adjusted EBITDA margin expansion for 2026.
• Expected annual non-GAAP operating expense savings of at least $150 million due to organizational simplification.
• Acceleration of U.S. SUBLOCADE dispense unit growth to mid-teens in 2026, driving 11% SUBLOCADE net revenue growth.
• Successful completion of Phase I of the Indivior Action Agenda and commencement of Phase II, indicating strategic execution.
• Inclusion in the S&P SmallCap 600 index, potentially increasing market visibility and liquidity.
• Shareholder approval for U.S. redomicile, streamlining corporate structure and aligning with primary market focus.
• Resolution of the legacy U.S. Department of Justice matter by paying the $295 million obligation in full, removing a significant legal overhang.
• Strong financial position with $473 million in cash and investments as of September 30, 2025, and a low 0.8x leverage ratio.
• Significant market opportunity to increase the use of long-acting injectable (LAI) buprenorphine medications in OUD treatment, with HCPs expecting usage to rise to 20-30% of the BMAT population.
• SUBLOCADE benefits from robust intellectual property protection with 12 Orange Book listed patents extending to 2031-2038, and 6 additional U.S. patent applications with potential expirations from 2035-2044.
• Positive early indicators from direct-to-consumer activation efforts, including a 2x increase in average daily search volume and 80% growth in FASTP Physician Locator usage.

Negatives

• Total Net Revenue guidance for 2026 represents a -3% year-over-year change at the midpoint compared to 2025 guidance.
• The decline in total net revenue is attributed to ongoing pressure on U.S. SUBOXONE Film, Rest of World (ROW) optimization, PERSERIS run-off, and the cessation of OPVEE promotion.
• Discontinuation of sales and marketing support for OPVEE and the run-off of PERSERIS indicate declining product lines outside of SUBLOCADE.

Risks

• Lower than expected future sales of products.
• Greater than expected impacts from competition.
• Unanticipated costs, including the effects of potential tariffs and retaliatory tariffs.
• Inability to identify efficiencies and fund additional investments that are expected to generate increased revenue.
• Unknown liabilities.
• The accuracy of estimates regarding expenses, revenue, and capital requirements.
• Market acceptance of long-acting injectables.
• The results of pending and future clinical trials.
• The decisions of relevant regulators.

Future Outlook

The company anticipates accelerating U.S. SUBLOCADE dispense unit growth to mid-teens in 2026, which is expected to drive 11% SUBLOCADE net revenue growth. Significant margin expansion is projected from a simplified operating model, leading to 35% adjusted EBITDA growth and a 14 percentage point increase in adjusted EBITDA margin. Indivior plans to leverage its strengthened financial profile to acquire future growth drivers in Phase III of its Action Agenda. Healthcare professionals are expected to increase LAI usage in the buprenorphine medication-assisted treatment (BMAT) population to 20-30%.

Management Comments

• Joe Ciaffoni, Chief Executive Officer: "We enter 2026 well positioned to execute on Phase II – Accelerate – which includes accelerating U.S. SUBLOCADE dispense unit growth and SUBLOCADE net revenue throughout 2026 and immediately accelerating adjusted EBITDA and cash flow at a faster rate."
• Ryan Preblick, Chief Financial Officer: "Our 2026 financial guidance reflects SUBLOCADE net revenue growth, driven by an acceleration in dispense units, and significant margin expansion from our simplified operating model. In 2026, we expect to grow SUBLOCADE net revenue by 11% at the midpoint of our guidance range while growing adjusted EBITDA by 35% and adjusted EBITDA margin by 14 percentage points."

Industry Context

Indivior operates in the critical opioid use disorder (OUD) treatment market, focusing on buprenorphine medication-assisted treatment (BMAT), particularly long-acting injectables (LAIs) like SUBLOCADE. The U.S. market presents a substantial opportunity, with 8.9 million individuals misusing opioids and 5.9 million diagnosed with OUD. Despite this, current LAI usage in the BMAT population is low at approximately 8%, indicating significant potential for expansion. Healthcare professionals anticipate LAI usage to increase to 20-30% of the BMAT population, aligning with Indivior's strategy to accelerate SUBLOCADE growth and invest in policy leadership to enhance access.

Comparison to Industry Standards

• Healthcare professionals (HCPs) expect long-acting injectable (LAI) usage to increase to 20-30% of the buprenorphine medication-assisted treatment (BMAT) population, indicating a substantial growth opportunity for SUBLOCADE, which is currently the #1 prescribed LAI in the U.S.
• Indivior's strategic focus on expanding LAI penetration in the U.S. BMAT category positions it to capitalize on this anticipated shift in treatment preferences and market growth for long-acting OUD therapies.

Corporate Governance

Legal Proceedings

• Concluded the legacy U.S. Department of Justice matter by paying in full the outstanding obligation of $295 million associated with the matter.

Stakeholder Impact

• Shareholders: Positive impact expected due to strong projected EBITDA growth, significant margin expansion, and a clear strategic focus on the high-growth SUBLOCADE product. The resolution of the DOJ matter and U.S. redomicile reduce operational and legal risks, potentially increasing shareholder value and market confidence. Inclusion in the S&P SmallCap 600 index may also enhance visibility and liquidity.
• Employees: Organizational simplification and restructuring efforts, while potentially involving workforce adjustments, are aimed at creating a more focused and efficient company, which could lead to long-term stability and growth opportunities.
• Customers (Patients): The company's continued dedication to developing and expanding access to evidence-based treatments for opioid use disorder (OUD), particularly SUBLOCADE, aims to improve patient outcomes and transform OUD into a recognized and treated chronic disease.
• Creditors: A strong financial position, evidenced by $473 million in cash and investments and a low 0.8x leverage ratio as of September 30, 2025, indicates robust creditworthiness and ability to manage debt obligations.

Next Steps

• Execute Phase II of the Indivior Action Agenda ('Accelerate'), focusing on accelerating U.S. SUBLOCADE dispense unit growth and net revenue, and immediately accelerating adjusted EBITDA and cash flow.
• Leverage strengthened financial profile to acquire next growth drivers as part of Phase III ('Breakout') of the Indivior Action Agenda, anticipated from H2 2026 and beyond.
• Advance state and federal policies that support durable access to increase long-term adoption of LAIs.
• Activate advocates to accelerate access, reduce system barriers, and increase awareness of OUD treatments.
• Continue investing at sustained levels to expand LAI penetration in the U.S. BMAT category.
• Expand patient awareness and engagement for SUBLOCADE, including ongoing direct-to-consumer (DTC) campaigns.
• Strengthen field force messaging and productivity and drive awareness of SUBLOCADE's updated label and unique rapid initiation protocol.

Key Dates

Recommendation

The company is demonstrating strong execution of its strategic agenda, leading to significant improvements in profitability and operational efficiency. The accelerated growth of SUBLOCADE, coupled with substantial cost savings and a simplified operating model, positions Indivior for robust financial performance in 2026. The resolution of the DOJ matter and the U.S. redomicile further de-risk the investment and streamline operations. The market for OUD treatment, particularly LAIs, presents a substantial growth opportunity that Indivior is well-positioned to capture.

Keywords

Indivior PLC, INDV, Financial Guidance 2026, SUBLOCADE, Opioid Use Disorder, OUD, Long-Acting Injectable, LAI, Adjusted EBITDA, Operating Expenses, Pharmaceuticals, Biotechnology, Healthcare, SEC Filing, 8-K, Corporate Presentation, Strategic Update, Buprenorphine, SUBOXONE Film, S&P SmallCap 600, Redomicile, DOJ Settlement